Top Markets
Coin of the day
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Classement en actions #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Prix de l'action
$0.07
Dernière synchronisation: 2024-11-12
Capitalisation boursière
$1.62M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Peak Bio, Inc. (PKBO)

Catégorie

Ratio P/S pour Peak Bio, Inc. (PKBO)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Peak Bio, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Peak Bio, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE